Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305559 · ClinicalTrials.gov registry record · Phase 3
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
A Phase 3 study of Coronary Artery Disease and Plaque, Atherosclerotic, sponsored by NewAmsterdam Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06305559 is a Phase 3 study of Coronary Artery Disease and Plaque, Atherosclerotic that is actively recruiting participants, run by NewAmsterdam Pharma. The registered enrollment target is 300 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06305559, a Phase 3 study of Coronary Artery Disease and Plaque, Atherosclerotic, is actively recruiting participants, sponsored by NewAmsterdam Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Study Locations (1)
Florida
- NGMR - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-05-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305559
The ClinicalTrials.gov registry entry for NCT06305559 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower). The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06305559 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06305559 about?
NCT06305559 is a clinical study titled "A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque". This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 m...
What is the current status of trial NCT06305559?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-05-16. Estimated completion is 2027-03.
What conditions does trial NCT06305559 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Plaque, Atherosclerotic, Lipidemia.
What interventions are being tested in trial NCT06305559?
The interventions under investigation include: Placebo (OTHER), obicetrapib 10 mg + ezetimibe 10 mg FDC daily (DRUG).
Who is sponsoring clinical trial NCT06305559?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305559 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
-
Cardiovascular Outcomes Of Diet Counseling
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.